PD-1

[Cancer Research] Emerging evidence indicates B cell activating factor (BAFF) to be an important cytokine for anti-tumor immunity. The authors generated a BAFF-overexpressing B16.F10 melanoma cell model and found that BAFF-expressing tumors grew more slowly in vivo than control tumors.

[Signal Transduction and Targeted Therapy] Fusobacterium nucleatum induces different immune responses in colorectal cancer (CRC) with different microsatellite-instability statuses. Scientists investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC.

[Scientific Reports] Scientists used mammary tumors with in situ immunomodulation consisting of intratumoral injections of Flt3L to mobilize conventional type-1 dendritic cells (cDC1s), local irradiation to induce immunogenic tumor cell death, and TLR3/CD40 stimulation to activate cDC1s.

[Science Immunology] Scientists showed that activation of the WNT/β-catenin signaling pathway contributed to the development of a noninflamed tumor microenvironment in tumors with high tumor mutation burden.

[Molecular Therapy-Oncolytics] Scientists found that oncolytic adenovirus conferred an effective ability to reduce ascites development and prolong overall survival.

[Clinical Cancer Research] Investigators identified EP4 as a specific target for prostate cancer immunotherapy and demonstrated that YY001 inhibited the growth of prostate tumors by regulating the immune microenvironment and strongly synergized with anti-programmed cell death protein-1 antibodies.